$CGNX

Moschner Matthew sold $1.6M of CGNX

Moschner Matthew (CEO & President) sold 24,962 shares of COGNEX CORP (CGNX) at an average of $64.01 ($63.61–$65.36, $1.60M total) across 5 trades on 2026-08-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Moschner Matthew
Published Aug 12, 2026, 8:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 8:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CGNX
Neutral
medium confidence
Mentioned
$CGNX
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CGNXNeutralLow
01

Why it matters

The disclosure updates the record of insider activity and may influence short-term sentiment, but it does not provide new operational, financial, or regulatory information about Cognex.

02

Market read

A $1.60M CEO sale is disclosed, but the 10b5-1 framing suggests limited fundamental implications.

03

What to watch

Because the trades are explicitly under a pre-arranged 10b5-1 plan, the sale may reflect scheduled liquidity rather than a view on near-term fundamentals.

Relevance 5/10Novelty 3/10Timing: SEC Form 4 filed 2026-08-12, covering sales executed 2026-08-11

Background

The article is an SEC Form 4 insider transaction disclosure for Cognex (CGNX) by CEO and President Matthew Moschner.

Company-level read

Ticker impact

$CGNXNeutralMedium confidence
Context

Cognex CEO and President Moschner Matthew sold about 24,962 shares in open-market trades totaling $1.60M, per a new SEC Form 4 filed today.

Expected impact

Likely limited near-term impact; any reaction should be muted unless traders treat the sale as a sentiment read-through.

Evidence & confidence

The filing specifies a Rule 10b5-1 pre-arranged plan and an open-market sale by the CEO, which typically reduces the likelihood of immediate fundamental news.

Market effects

No direct sector read-through; insider sales under 10b5-1 are generally not sector-moving.

None indicated.

None indicated.

Counterpoint

Traders may still interpret a CEO sale as a bearish sentiment signal, especially if it coincides with other negative company-specific catalysts not mentioned here.

Key entities

  • CGNX

    Cognex Corp, the issuer of the insider transaction disclosed on Form 4.

  • Matthew Moschner

    CEO and President who sold shares in open-market transactions under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AMBAMedAI 8/10

Usain Bolt Just Got an AI Rival – Meet the Stocks Behind It

Unitree Robotics, a Chinese company, unveiled a humanoid robot 'Superman' claiming it runs faster than Usain Bolt. The company's IPO on the Shanghai Stock Exchange saw shares surge 460%, valuing it at $50 billion. Investors are betting on the humanoid robotics sector and its supply chain, including companies like Ambarella, Ouster, Cognex, Regal Rexnord, and Harmonic Drive Systems, which saw gains in July.

$CGNXHighAI 8/10

Enabled Machine Vision Drives Growth – Metrology and Quality News

Cognex Corporation reported record Q2 2026 revenue of $291M, up 17% YoY, driven by demand across major markets and AI-enabled vision applications. Profitability improved significantly, with operating income doubling to $86M and operating margin increasing to 29.4%. The company highlighted the launch of OneVision, its AI-powered machine vision platform, and reaffirmed its growth strategy focused on diversification and scalability. Cognex issued full-year 2026 guidance for strong double-digit reve

$CGNXMedAI 9/10

Cognex (CGNX) Q2 2026 Earnings Call Transcript

Cognex (CGNX) reported Q2 2026 revenue of $291 million, up 17% (16% constant currency). Adjusted EBITDA margin rose to 32.2%, and adjusted EPS was $0.45. Full-year 2026 guidance: revenue $1.13 to $1.15 billion, adjusted EPS $1.64 to $1.68, and adjusted EBITDA margin 29% to 31%. Management raised outlooks for logistics, packaging, electronics, and semiconductors.

$CGNXMed

Why Cognex (CGNX) Shares Are Sliding Today

Cognex (CGNX) shares fell about 4% in the afternoon after HSBC downgraded the stock to Hold from Buy and cut its price target to $65 from $94. The move followed mixed analyst views and valuation concerns. After the initial drop, CGNX traded around $64.53, down about 3.5% from the prior close.

$CGNXMedAI 8/10

CGNX Q2 Deep Dive: AI-Driven Growth and Product Diversification Shape Outlook

Cognex reported Q2 revenue of $291.3M, slightly below estimates of $293.3M, but beat on adjusted EPS of $0.45 vs $0.42 and adjusted EBITDA of $93.66M vs $87.98M. Operating margin rose to 29.4%. Q3 CY2026 revenue guidance midpoint is $310M and full-year adjusted EPS is $1.66. The company cited OneVision adoption, ~4,500 new customers YTD, and margin gains from cost reduction.

$CGNXMedAI 8/10

Cognex Reports Second Quarter 2026 Results

Cognex (NASDAQ: CGNX) reported Q2 2026 revenue of $291 million, up 17% year over year, with operating margin at 29.4% and adjusted diluted EPS of $0.45. Net income was $73 million. The company said it has $755 million cash and no debt, declared a $0.085 dividend, and issued 2026 guidance for double-digit revenue growth.